{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:37:10Z","timestamp":1792816630050,"version":"4.5.0"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bbrc.2026.154671","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:44:40Z","timestamp":1790725480000},"page":"154671","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Light on dark matter: Epigenetic drugs as a tool to reveal the hidden antigen repertoire"],"prefix":"10.1016","volume":"838","author":[{"given":"Daniil D.","family":"Romashin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8447-6417","authenticated-orcid":false,"given":"Olga V.","family":"Shlepova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena V.","family":"Bogoslovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German A.","family":"Shipulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2026.154671_bib1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41698-025-01003-7","article-title":"Epigenetic regulators in cancer therapy and progression","volume":"9","author":"Marei","year":"2025","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc1279","article-title":"The history of cancer epigenetics","volume":"4","author":"Feinberg","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib3","first-page":"3104","article-title":"The role of epigenetics in cancer: from pathways to the clinic, J. Fam","volume":"14","author":"Almalki","year":"2025","journal-title":"Med. Prim. Care"},{"key":"10.1016\/j.bbrc.2026.154671_bib4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41392-024-02039-0","article-title":"Epigenetics-targeted drugs: current paradigms and future challenges","volume":"9","author":"Dai","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154671_bib5","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbrc.2026.154671_bib6","first-page":"1085","article-title":"Epidrugs in cancer: mechanisms, applications, and future direction","volume":"28","author":"Bibi","year":"2026","journal-title":"Clin. Transl. Oncol. Off. Publ. Fed. Span. Oncol. Soc. Natl. Cancer Inst. Mex."},{"key":"10.1016\/j.bbrc.2026.154671_bib7","article-title":"Current landscape and future directions of neoantigen vaccines: a new era of personalized cancer immunotherapy","author":"Wang","year":"2026","journal-title":"Innovation"},{"key":"10.1016\/j.bbrc.2026.154671_bib8","article-title":"Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation, Explor. Target","volume":"6","author":"Naffaa","year":"2025","journal-title":"Anti-Tumor Ther"},{"key":"10.1016\/j.bbrc.2026.154671_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aea4059","article-title":"A synergistic interaction between PRMT5 and LSD1 inhibitors in AML","volume":"12","author":"Param","year":"2026","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154671_bib10","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41467-023-36826-0","article-title":"Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response","volume":"14","author":"Barczak","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib11","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41541-025-01107-y","article-title":"Endogenous viral elements constitute a complementary source of antigens for personalized cancer vaccines","volume":"10","author":"Garde","year":"2025","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.bbrc.2026.154671_bib12","article-title":"Bright side of the dark genome: antigens for next-gen cancer vaccines","volume":"14","author":"Wang","year":"2026","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib13","doi-asserted-by":"crossref","first-page":"10903","DOI":"10.2147\/OTT.S217767","article-title":"DNA methyltransferase inhibitors: catalysts for antitumour immune responses","volume":"12","author":"Dan","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.bbrc.2026.154671_bib14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.bbrc.2019.06.060","article-title":"Structure of PCNA in complex with DNMT1 PIP box reveals the basis for the molecular mechanism of the interaction","volume":"516","author":"Jimenji","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib15","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2026.154671_bib16","doi-asserted-by":"crossref","first-page":"7130","DOI":"10.1038\/s41467-022-34779-4","article-title":"Structural basis for activation of DNMT1","volume":"13","author":"Kikuchi","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib17","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1080\/09553002.2025.2607004","article-title":"Promoter methylation in key DNA damage response genes shows a positive correlation with cumulative dose in chronically low-dose radiation-exposed individuals","volume":"102","author":"Priya","year":"2026","journal-title":"Int. J. Radiat. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/curroncol32020088","article-title":"The role of the DNA methyltransferase family and the therapeutic potential of DNMT inhibitors in tumor treatment","volume":"32","author":"Kim","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib19","first-page":"58","article-title":"DNA methyl transferase 1: regulatory mechanisms and implications in health and disease","volume":"2","author":"Dhe-Paganon","year":"2011","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.sbi.2011.08.004","article-title":"Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes","volume":"21","author":"Lombardi","year":"2011","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib21","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.2217\/fon-2020-1244","article-title":"EZH2 inhibition by tazemetostat: mechanisms of action, safety and efficacy in relapsed\/refractory follicular lymphoma","volume":"17","author":"Julia","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bbrc.2026.154671_bib23","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/cells14241997","article-title":"Next-generation HDAC inhibitors: advancing zinc-binding group design for enhanced cancer therapy","volume":"14","author":"Hawash","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.154671_bib24","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1200\/JCO.2012.43.7251","volume":"31","author":"Yardley","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/ph17060752","article-title":"Novel histone deacetylase (HDAC) inhibitor induces apoptosis and suppresses invasion via E-cadherin upregulation in pancreatic ductal adenocarcinoma (PDAC)","volume":"17","author":"Schiedlauske","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bbrc.2026.154671_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116251","article-title":"Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents","volume":"42","author":"El-Awady","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154671_bib27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nm1160","article-title":"Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway","volume":"11","author":"Insinga","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.154671_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2024.105884","article-title":"Selective inhibition of HDAC6 by N-acylhydrazone derivative reduces the proliferation and induces senescence in carcinoma hepatocellular cells","volume":"99","author":"Ferreira-Silva","year":"2024","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.bbrc.2026.154671_bib29","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","article-title":"The polycomb group protein EZH2 directly controls DNA methylation","volume":"439","author":"Vir\u00e9","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154671_bib30","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.3390\/molecules29245817","article-title":"Targeting EZH2 in cancer: mechanisms, pathways, and therapeutic potential","volume":"29","author":"Gilardini Montani","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2026.154671_bib31","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-024-04658-4","article-title":"Pharmacology and pharmacokinetics of tazemetostat","volume":"93","author":"Orleni","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154671_bib33","doi-asserted-by":"crossref","first-page":"e493","DOI":"10.1016\/S2352-3026(22)00134-X","article-title":"SHR2554, an EZH2 inhibitor, in relapsed or refractory mature lymphoid neoplasms: a first-in-human, dose-escalation, dose-expansion, and clinical expansion phase 1 trial","volume":"9","author":"Song","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bbrc.2026.154671_bib34","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/S1470-2045(24)00503-5","article-title":"Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, single-arm, multicenter, phase 2, VALENTINE-PTCL01 Study","volume":"25","author":"Zinzani","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.102971","article-title":"Independent transcriptomic and proteomic regulation by type I and II protein arginine methyltransferases","volume":"24","author":"Maron","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2026.154671_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.15698\/cst2020.08.228","article-title":"PRMT5 function and targeting in cancer","volume":"4","author":"Kim","year":"2020","journal-title":"Cell Stress"},{"key":"10.1016\/j.bbrc.2026.154671_bib37","doi-asserted-by":"crossref","first-page":"13793","DOI":"10.1021\/acs.jmedchem.2c01000","article-title":"Discovery and biological characterization of PRMT5:MEP50 protein:protein interaction inhibitors","volume":"65","author":"Asberry","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154671_bib38","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41467-024-46495-2","article-title":"PRMT5 is an actionable therapeutic target in CDK4\/6 inhibitor-resistant ER+\/RB-deficient breast cancer","volume":"15","author":"Lin","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118754","article-title":"Targeting PRMT5 in cancer: mechanistic insights and clinical progress","volume":"193","author":"Lee","year":"2025","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bbrc.2026.154671_bib40","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41419-020-02771-9","article-title":"PRMT5 promotes cancer cell migration and invasion through the E2F pathway","volume":"11","author":"Barczak","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154671_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41419-023-05630-5","article-title":"Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-\u03b2 signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors","volume":"14","author":"Hong","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbrc.2026.154671_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108286","article-title":"EPZ015666, a selective protein arginine methyltransferase 5 (PRMT5) inhibitor with an antitumour effect in retinoblastoma","volume":"202","author":"Liu","year":"2021","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbrc.2026.154671_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.218075","article-title":"Cracking PRMT5: mechanistic insights, clinical advances, and AI-driven strategies","volume":"634","author":"Alipourgivi","year":"2025","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbrc.2026.154671_bib44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/s41392-023-01647-6","article-title":"Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154671_bib45","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/pcmr.13174","article-title":"BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment","volume":"37","author":"Tseng","year":"2024","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.bbrc.2026.154671_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100893","article-title":"TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: a multicenter, phase 1 trial","volume":"7","author":"Zhang","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.bbrc.2026.154671_bib47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2019.07.013","article-title":"Efficacy of novel bromodomain and extraterminal inhibitors in combination with chemotherapy for castration-resistant prostate cancer","volume":"4","author":"V\u00e1zquez","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib48","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s12276-020-00542-2","article-title":"LSD1: more than demethylation of histone lysine residues","volume":"52","author":"Perillo","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154671_bib49","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.3390\/curroncol30020164","article-title":"Lysine-specific demethylase 1 (LSD1)-mediated epigenetic modification of immunogenicity and immunomodulatory effects in breast cancers","volume":"30","author":"Lee","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials","volume":"14","author":"Noce","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154671_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104397","article-title":"Epigenetic roles of lysine-specific demethylase 1 (LSD1) in cancer metabolism","volume":"30","author":"Cheng","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbrc.2026.154671_bib52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41392-026-02637-0","article-title":"Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154671_bib53","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/ng.3889","article-title":"DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats","volume":"49","author":"Brocks","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2026.154671_bib54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13148-020-00937-y","article-title":"Low-dose DNA demethylating therapy induces reprogramming of diverse cancer-related pathways at the single-cell level","volume":"12","author":"Takeshima","year":"2020","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.bbrc.2026.154671_bib55","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/s41598-020-60409-4","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","volume":"10","author":"Moufarrij","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154671_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107271","article-title":"Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy","volume":"206","author":"Yang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bbrc.2026.154671_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104602","article-title":"Priming therapy by targeting enhancer-initiated pathways in patient-derived pancreatic cancer cells","volume":"92","author":"Fraunhoffer","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bbrc.2026.154671_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13148-026-02051-x","article-title":"Differential transcriptomic modulation by histone deacetylase inhibitor SAHA in LUAD and LUSC","volume":"18","author":"Wang","year":"2026","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.bbrc.2026.154671_bib59","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13402-023-00882-x","article-title":"Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and ex vivo in colon cancer","volume":"47","author":"Finnegan","year":"2023","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117535","article-title":"Opposing outcomes of short- and long-term epigenetic therapy in breast cancer: implications for chemotherapy response","volume":"243","author":"Ramadan","year":"2026","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbrc.2026.154671_bib61","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1158\/0008-5472.CAN-24-0398","article-title":"Comprehensive target engagement by the EZH2 inhibitor Tulmimetostat allows for targeting of ARID1A mutant cancers","volume":"84","author":"Keller","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2026.154671_bib62","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.70197","article-title":"DNA methyltransferase inhibitors in hematological malignancies and solid tumors","volume":"158","author":"Wenger","year":"2026","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104573","article-title":"Association of epigenetic landscapes with heterogeneity and plasticity in pancreatic cancer","volume":"206","author":"Manoukian","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.bbrc.2026.154671_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.110231","article-title":"Throwing a spotlight on genomic dark matter: the power and potential of transposon-insertion sequencing","volume":"301","author":"Nolan","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154671_bib65","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nature11247","article-title":"An integrated encyclopedia of DNA elements in the human genome","volume":"489","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154671_bib66","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/biology15070538","article-title":"Long Non-Coding RNA\u2013derived peptides as a novel source of tumor neoantigens: expanding the immunopeptidome beyond canonical coding regions","volume":"15","author":"L\u00f3pez-Calvo","year":"2026","journal-title":"Biology"},{"key":"10.1016\/j.bbrc.2026.154671_bib67","doi-asserted-by":"crossref","first-page":"5913","DOI":"10.3390\/ijms26125913","article-title":"LncRNA-encoded micropeptides: expression validation, translational mechanisms, and roles in cellular metabolism","volume":"26","author":"Ho","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154671_bib68","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s12672-025-02387-5","article-title":"Interactions between long non-coding RNAs and m6 A modification in cancer","volume":"16","author":"Zhang","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib69","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.3390\/ijms25137252","article-title":"Genomic and epigenomic biomarkers of immune checkpoint immunotherapy response in melanoma: current and future perspectives","volume":"25","author":"Hossain","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbrc.2026.154671_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008402","article-title":"Circular RNA as a source of neoantigens for cancer vaccines","volume":"12","author":"Ren","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib71","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virs.2022.01.019","article-title":"The diversity and evolution of retroviruses: perspectives from viral \u201cfossils,\u201d","volume":"37","author":"Zheng","year":"2022","journal-title":"Virol. Sin."},{"key":"10.1016\/j.bbrc.2026.154671_bib72","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3389\/fonc.2013.00246","article-title":"HERV-K(HML-2), the best preserved family of HERVs: endogenization, expression, and implications in health and disease","volume":"3","author":"Hohn","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib73","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1186\/1471-2164-9-354","article-title":"Expression patterns of transcribed human endogenous retrovirus HERV-K(HML-2) loci in human tissues and the need for a HERV Transcriptome Project","volume":"9","author":"Flockerzi","year":"2008","journal-title":"BMC Genom."},{"key":"10.1016\/j.bbrc.2026.154671_bib74","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/1742-4690-8-90","article-title":"Identification, characterization, and comparative genomic distribution of the HERV-K (HML-2) group of human endogenous retroviruses","volume":"8","author":"Subramanian","year":"2011","journal-title":"Retrovirology"},{"key":"10.1016\/j.bbrc.2026.154671_bib75","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010099","article-title":"HERV-derived epitopes represent new targets for T-cell-based immunotherapies in ovarian cancer","volume":"13","author":"Bonaventura","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib76","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167712","article-title":"Proteogenomic identification of an immunogenic antigen derived from human endogenous retrovirus in renal cell carcinoma","volume":"8","author":"Kobayashi","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2026.154671_bib77","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/ajh.26647","article-title":"HERVs characterize normal and leukemia stem cells and represent a source of shared epitopes for cancer immunotherapy","volume":"97","author":"Alcazer","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bbrc.2026.154671_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/epigenomes10010011","article-title":"Analysis of HERV-K (HML2) expression in colorectal cancer samples","volume":"10","author":"Obrezanenko","year":"2026","journal-title":"Epigenomes"},{"key":"10.1016\/j.bbrc.2026.154671_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1150212","article-title":"Introns: the \u201cdark matter\u201d of the eukaryotic genome","volume":"14","author":"Girardini","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbrc.2026.154671_bib80","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-43687-2","article-title":"Identification of immunogenic neoantigens from intron retention in colorectal cancer","volume":"16","author":"Manoharan","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2026.154671_bib81","doi-asserted-by":"crossref","first-page":"5689","DOI":"10.3390\/cancers15235689","article-title":"Pan-cancer profiling of intron retention and its clinical significance in diagnosis and prognosis","volume":"15","author":"Huang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2026.154671_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2024.189126","article-title":"The neoantigens derived from transposable elements - a hidden treasure for cancer immunotherapy","volume":"1879","author":"Hu","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib83","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.tig.2025.04.011","article-title":"Advances in understanding LINE-1 regulation and function in the human genome","volume":"41","author":"Li","year":"2025","journal-title":"Trends Genet."},{"key":"10.1016\/j.bbrc.2026.154671_bib84","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s42003-021-02007-2","article-title":"Increased expression of peptides from non-coding genes in cancer proteomics datasets suggests potential tumor neoantigens","volume":"4","author":"Xiang","year":"2021","journal-title":"Commun. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib85","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1158\/2767-9764.CRC-23-0289","article-title":"Cancer relevance of circulating antibodies against LINE-1 antigens in humans","volume":"3","author":"Vylegzhanina","year":"2023","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib86","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/15384101.2018.1442623","article-title":"Reactivation of endogenous retroviral elements via treatment with DNMT- and HDAC-inhibitors","volume":"17","author":"Daskalakis","year":"2018","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bbrc.2026.154671_bib87","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s41589-022-01024-4","article-title":"PRMT inhibition induces a viral mimicry response in triple-negative breast cancer","volume":"18","author":"Wu","year":"2022","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib88","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41420-025-02820-2","article-title":"The expression, regulation, and function of human endogenous retroviruses in genitourinary cancers","volume":"11","author":"Ma","year":"2025","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.bbrc.2026.154671_bib89","article-title":"Cancer testis antigens: emerging therapeutic targets leveraging genomic instability in cancer","volume":"32","author":"Naik","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179501","article-title":"Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells","volume":"12","author":"Siebenk\u00e4s","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2026.154671_bib91","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1111\/j.1349-7006.2010.01732.x","article-title":"Vaccination with peptides derived from cancer\u2010testis antigens in combination with CpG\u20107909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma","volume":"101","author":"Iwahashi","year":"2010","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbrc.2026.154671_bib92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.trecan.2024.10.008","article-title":"Generation of tumor neoantigens by RNA splicing perturbation","volume":"11","author":"Rosenberg-Mogilevsky","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.114597","article-title":"Pharmacological perturbation of splicing elicits SMG1 reduction: implications for cancer therapy","volume":"29","author":"Barainka","year":"2026","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2026.154671_bib94","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1038\/s44321-026-00499-1","article-title":"PRMT5-mediated intron retention triggers innate and adaptive immunity against cancer","volume":"18","author":"Blaszczak","year":"2026","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.bbrc.2026.154671_bib95","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.3390\/cells14211699","article-title":"The CoREST complex regulates alternative splicing by the transcriptional regulation of RNA processing genes in melanoma cells","volume":"14","author":"Khan","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.154671_bib96","article-title":"CoREST complex inhibition alters RNA splicing to promote neoantigen expression and enhance tumor immunity","volume":"11","author":"Fisher","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2026.154671_bib97","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/s41588-024-01880-x","article-title":"Epigenetic therapy potentiates transposable element transcription to create tumor-enriched antigens in glioblastoma cells","volume":"56","author":"Jang","year":"2024","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bbrc.2026.154671_bib98","first-page":"992","article-title":"Cancer cell type-specific derepression of transposable elements by inhibition of chromatin modifier enzymes, Commun","volume":"8","author":"Patel","year":"2025","journal-title":"Biol"},{"key":"10.1016\/j.bbrc.2026.154671_bib99","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adk4423","article-title":"Select EZH2 inhibitors enhance viral mimicry effects of DNMT inhibition through a mechanism involving NFAT:AP-1 signaling","volume":"10","author":"Chomiak","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154671_bib100","doi-asserted-by":"crossref","first-page":"6731","DOI":"10.1038\/s41467-023-42417-w","article-title":"DNMT and HDAC inhibition induces immunogenic neoantigens from human endogenous retroviral element-derived transcripts","volume":"14","author":"Goyal","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib101","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41375-025-02628-0","article-title":"Induction of p53-mediated apoptosis by azacitidine in patient-derived xenograft follicular helper T-cell lymphoma model","volume":"39","author":"Tari Crochet","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154671_bib102","author":"Depil"},{"key":"10.1016\/j.bbrc.2026.154671_bib103","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abj3671","article-title":"Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy","volume":"8","author":"Bonaventura","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154671_bib104","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41698-026-01370-9","article-title":"HERVOminer: a sequence similarity-based approach for recognizing endogenous retrovirus origin of the peptidome","volume":"10","author":"Wu","year":"2026","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib105","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6359","article-title":"Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer","volume":"8","author":"Merlotti","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.bbrc.2026.154671_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110916","article-title":"Single-cell RNA-seq-based proteogenomics identifies glioblastoma-specific transposable elements encoding HLA-I-presented peptides","volume":"39","author":"Bont\u00e9","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.bbrc.2026.154671_bib107","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chembiol.2021.07.015","article-title":"Splicing modulators elicit global translational repression by condensate-prone proteins translated from introns","volume":"29","author":"Chhipi-Shrestha","year":"2022","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154507","article-title":"Modulation of long non-coding RNAs by resveratrol as a potential therapeutic approach in cancer: a comprehensive review","volume":"246","author":"Asemi","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.bbrc.2026.154671_bib109","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fgene.2019.00514","article-title":"Curcumin as an alternative epigenetic modulator: mechanism of action and potential effects","volume":"10","author":"Hassan","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.bbrc.2026.154671_bib110","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adn3628","article-title":"Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort","volume":"10","author":"Camarena","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154671_bib111","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/s41467-024-46408-3","article-title":"Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides","volume":"15","author":"Ferreira","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib112","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s44319-024-00128-3","article-title":"The phosphatase inhibitor LB-100 creates neoantigens in colon cancer cells through perturbation of mRNA splicing","volume":"25","author":"Dias","year":"2024","journal-title":"EMBO Rep."},{"key":"10.1016\/j.bbrc.2026.154671_bib113","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adv6445","article-title":"Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy","volume":"11","author":"Cai","year":"2025","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbrc.2026.154671_bib114","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41590-023-01664-1","article-title":"Non-mutational neoantigens in disease","volume":"25","author":"Stern","year":"2024","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2026.154671_bib115","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41577-020-0390-6","article-title":"A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion","volume":"21","author":"Dersh","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbrc.2026.154671_bib116","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tig.2024.09.003","article-title":"The cryptic immunopeptidome in health and disease","volume":"41","author":"Kina","year":"2025","journal-title":"Trends Genet."},{"key":"10.1016\/j.bbrc.2026.154671_bib117","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1189\/jlb.1113599","article-title":"Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors","volume":"95","author":"Ant\u00f3n","year":"2014","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbrc.2026.154671_bib118","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2208509120","article-title":"Major histocompatibility class I antigenic peptides derived from translation of pre-mRNAs generate immune tolerance","volume":"120","author":"Sroka","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2026.154671_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2025.09.372","article-title":"P1.11.72 Phase II study of combination azacitidine and entinostat and nivolumab in patients with metastatic non-small cell lung cancer","volume":"20","author":"Marrone","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib120","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13148-025-01856-6","article-title":"Epigenetic regulators combined with tumour immunotherapy: current status and perspectives","volume":"17","author":"Zhang","year":"2025","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.bbrc.2026.154671_bib121","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.18632\/oncotarget.1542","article-title":"Alterations of immune response of non-small cell lung cancer with Azacytidine","volume":"4","author":"Wrangle","year":"2013","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2026.154671_bib122","article-title":"Epigenetic therapeutics to overcome resistance against immune checkpoint inhibitors (ICI) in hepatocellular carcinoma (HCC): a proof-of-concept clinical trial","volume":"55","author":"Chan","year":"2025","journal-title":"Lancet Reg. Health West. Pac."},{"key":"10.1016\/j.bbrc.2026.154671_bib123","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12026-025-09678-7","article-title":"Targeting epigenetic modifications as an emerging immunotherapeutic strategy for cancers","volume":"73","author":"Kumar","year":"2025","journal-title":"Immunol. Res."},{"key":"10.1016\/j.bbrc.2026.154671_bib124","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41392-025-02266-z","article-title":"Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance","volume":"10","author":"Song","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.bbrc.2026.154671_bib125","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154671_bib126","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2026.154671_bib127","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154671_bib128","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41586-025-10004-2","article-title":"Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC","volume":"651","author":"Sahin","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154671_bib129","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.136368","article-title":"Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer","volume":"5","author":"Kim","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.bbrc.2026.154671_bib130","article-title":"Low-dose decitabine enhances the efficacy of viral cancer vaccines for immunotherapy","volume":"32","author":"Russo","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.bbrc.2026.154671_bib131","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1021\/acsptsci.5c00729","article-title":"The future of epigenetics: emerging technologies and clinical applications","volume":"9","author":"Iyer","year":"2026","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bbrc.2026.154671_bib132","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.3390\/cancers16112155","article-title":"Small-molecule inhibition of CBX4\/7 hypersensitises homologous recombination-impaired cancer to radiation by compromising CtIP-mediated DNA end resection","volume":"16","author":"Osborne","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.bbrc.2026.154671_bib133","doi-asserted-by":"crossref","DOI":"10.1172\/JCI200564","article-title":"In vivo CRISPR screens identify CBX4 as an epigenetic regulator for cancer immunotherapy","volume":"136","author":"Ma","year":"2026","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.bbrc.2026.154671_bib134","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/s41467-025-57005-3","article-title":"Potent and selective SETDB1 covalent negative allosteric modulator reduces methyltransferase activity in cells","volume":"16","author":"Uguen","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2026.154671_bib135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41586-021-04228-1","article-title":"Genome surveillance by HUSH-mediated silencing of intronless mobile elements","volume":"601","author":"Seczynska","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2026.154671_bib136","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41375-024-02509-y","article-title":"EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in CML","volume":"39","author":"Brunmeir","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2026.154671_bib137","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3390\/cells9061511","article-title":"Mechanistic involvement of long non-coding RNAs in oncotherapeutics resistance in triple-negative breast cancer","volume":"9","author":"Kansara","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bbrc.2026.154671_bib138","series-title":"Epigenetics Cancer Prev.","first-page":"169","article-title":"Chapter 8 - epigenetic mechanisms of resveratrol and its analogs in cancer prevention and treatment","author":"Kumar","year":"2019"},{"key":"10.1016\/j.bbrc.2026.154671_bib139","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2174\/0109298673256601231009054714","article-title":"Modulation of long non-coding RNAs and microRNAs by quercetin as a potential therapeutical approach in cancer: a comprehensive review","volume":"32","author":"Asemi","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbrc.2026.154671_bib140","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/s41587-024-02420-y","article-title":"A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy","volume":"43","author":"Huber","year":"2025","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbrc.2026.154671_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.113448","article-title":"NovumRNA: accurate prediction of non-canonical tumor antigens from RNA sequencing data","volume":"28","author":"Ausserhofer","year":"2025","journal-title":"iScience"},{"key":"10.1016\/j.bbrc.2026.154671_bib142","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcad024","article-title":"CrypticProteinDB: an integrated database of proteome and immunopeptidome derived non-canonical cancer proteins","volume":"5","author":"Othoum","year":"2023","journal-title":"NAR Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib143","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaf314","article-title":"Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas","volume":"26","author":"Ran","year":"2025","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.bbrc.2026.154671_bib144","doi-asserted-by":"crossref","first-page":"115","DOI":"10.18632\/oncoscience.364","article-title":"Drug-induced activation of \u201cjunk\u201d DNA \u2013 a path to combat cancer therapy resistance?","volume":"4","author":"Classon","year":"2017","journal-title":"Oncoscience"},{"key":"10.1016\/j.bbrc.2026.154671_bib145","article-title":"Dual roles of human endogenous retroviruses in cancer progression and antitumor immune response","volume":"1879","author":"Yang","year":"2024","journal-title":"Biochim. Biophys. Acta BBA - Rev. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib146","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108200","article-title":"p53-mediated regulation of LINE1 retrotransposon-derived R-loops","volume":"301","author":"Paul","year":"2025","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2026.154671_bib147","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012217","article-title":"Shared epitopes create safety and efficacy concerns in several cancer vaccines","volume":"13","author":"Kellermann","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bbrc.2026.154671_bib148","first-page":"21","article-title":"Stochastic demethylation and redundant epigenetic suppressive mechanisms generate highly heterogeneous responses to pharmacological DNA methyltransferase inhibition","volume":"44","author":"Jakobsen","year":"2025","journal-title":"J. Exp. Clin. Cancer Res. CR"},{"key":"10.1016\/j.bbrc.2026.154671_bib149","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/978-1-0716-3646-6_25","article-title":"Deep learning-assisted analysis of immunopeptidomics data","volume":"2758","author":"Gabriel","year":"2024","journal-title":"Methods Mol. Biol."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26014361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X26014361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:48:42Z","timestamp":1792813722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X26014361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":148,"alternative-id":["S0006291X26014361"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154671","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Light on dark matter: Epigenetic drugs as a tool to reveal the hidden antigen repertoire","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2026.154671","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154671"}}